Clinical Trial

Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations

Study acronym: NEOASIS
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
In this study, the efficacy of botensilimab and balstilimab in mismatch repair deficient (dMMR) and mismatch repair proficient (pMMR) tumors will be assessed.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-02-22; most recent amendment 2026-03-03.
Trial Details
NCT Number NCT06279130
Lead Sponsor The Netherlands Cancer Institute
Collaborators: Agenus Inc.
Conditions Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors
Enrollment 133 participants
Start Date 2024-01-29
Primary Completion 2029-01-29 (estimated)
Study Completion 2034-01-29 (estimated)
Updated on ClinicalTrials.gov 2026-03-05